Novabay Pharmaceuticals (NBY) Proxy Filing summary

Executive summary

• The annual meeting will address 11 proposals, including director elections, executive compensation, auditor ratification, major capital structure changes, and approvals related to a transformative investment transaction with David E. Lazar, who is set to become the controlling shareholder and CEO upon full conversion of preferred shares.

• The company has divested its main revenue-generating assets and is pivoting to pursue a strategic transaction (Post-Investment Transaction) with a new operating company, using proceeds from the $6 million investment by Mr. Lazar.

• A special cash dividend of $0.80 per share was declared for common shareholders, funded by the investment proceeds.

• The board recommends voting in favor of all proposals, which are critical for completing the investment transaction and enabling future growth opportunities.

Voting matters and shareholder proposals

• Proposals include electing three Class III directors, advisory votes on executive compensation and its frequency, ratification of the external auditor, approval of share issuances upon conversion of preferred stock, amendments to increase authorized common and preferred shares, a reverse stock split, and payment of equity to resigning directors.

• Approval is sought for a reverse stock split (1-for-2 to 1-for-10), increasing authorized common shares to 1.5 billion and preferred shares to 10 million, and amending the 2017 Omnibus Incentive Plan.

• Voting commitments from major shareholders and warrant holders ensure significant support for all proposals.

Board of directors and corporate governance

• The board currently consists of eight directors, with a mix of independent and non-independent members.

• Mr. Lazar was appointed CEO and director at the first closing; he will gain the right to nominate up to three additional directors and become board chair after the final closing.

• Five non-employee directors have agreed to resign upon completion of the investment transaction and payment of equity consideration.

• The board has established a Special Transaction Committee to oversee the investment transaction and related matters.